Iclusig (ponatinib) / Takeda, Otsuka, Incyte - LARVOL DELTA

In-silico, in-vitro, and proteomics analyses on repurposed drugs in targeting the small GTPase, Rho subfamily protein (Rho GTPase), and putative Rho GTPase-activating protein (RhoGAP) of Giardia lamblia. (PubMed, J Genet Eng Biotechnol) - "Giardia lamblia is a globally prevalent protozoan responsible for Giardiasis, an intestinal disease commonly treated with nitroimidazoles such as metronidazole, tinidazole, and albendazole...Target sequence analysis revealed Dextromethorphan and Azathioprine as candidate Rho GTPase inhibitors, and Imatinib, Dasatinib, and Ponatinib as RhoGAP inhibitors...These findings highlight RhoGAP as a promising therapeutic target in G. lamblia, with Dasatinib showing potential as a repurposed treatment for Giardiasis. Proteomic data are publicly available in the MASSIVE database under identifier MSV000097321."

Journal • Preclinical • Gastrointestinal Disorder • Infectious Disease

Characterization of pityriasis rubra pilaris with hematological malignancies: Paraneoplastic disease and targeted therapy reactions (ASH 2025) - "The ALL patient was related to ponatinib, the non-Hodgkin's lymphoma case was related to copanlisib, 2 CLL patients were related to duvelisib, and 2 CLL were related to idealisib...With regards to paraneoplastic treatment, topical treatment included corticosteroids, emollients, topical urea, retinoids, and fluorouracil. Systemic treatments included methotrexate, systemic corticosteroids, and phototherapy...Specialists should maintain a high index of suspicion for PRP as a paraneoplastic signal or drug-related adverse event. Future studies are needed to elucidate such presentations and guide management."

Chronic Lymphocytic Leukemia • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology

Model-based evaluation of clinical outcomes for ponatinib versus 2G TKIs in third-line chronic myeloid leukemia (CML) (ASH 2025) - "Objectives: To estimate and compare ponatinib versus 2G TKIs (bosutinib, dasatinib, nilotinib) in adult patients with CP-CML who have received two prior TKIs, focusing on long-term clinical and economic outcomes: survival (life years), quality-adjusted survival (QALYs), and healthcare resource utilization (outpatient, inpatient and emergency department visits). This model-based analysis suggests that ponatinib offers substantial clinical benefits over 2G TKIs in the third-line treatment of CP-CML, particularly for patients with the T315I mutation. These findings support the clinical value of ponatinib as a preferred treatment option in this setting, with the potential to improve survival outcomes and reduce burden to the healthcare system."

Clinical • Clinical data • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia

Erythroblastic sarcoma transformation from chronic myeloid leukaemia: A case report (ASH 2025) - "Dasatinib was held due to concerns of drug-related pleural effusion and disease progression...She received three cycles of high-dose cytarabine and ponatinib...She continues to receive ponatinib with plans to add Azacitidine... Myeloid Sarcoma is a rare form of myeloid malignancies, which is usually composed of myeloblasts, Monoblasts or megakaryoblasts. Erythroblastic sarcoma is a rare form of MS which is associated with a poor prognosis. ES Transformation from CML is extremely rare, with only a few cases reported in the literature."

Case report • Clinical • IO biomarker • Acute Myelogenous Leukemia • Cardiovascular • Chronic Myeloid Leukemia • Hematological Malignancies • Hypertension • Leukemia • Lymphoma • Musculoskeletal Pain • Respiratory Diseases • Sarcoma • Solid Tumor • ABL1 • BCR • CD123 • CD33 • CD36 • CD38 • CD7 • IL3RA • KIT • SCARB1 • TFRC

Chronic myeloid leukemia and ASXL1 mutations: A distinct entity requiring special attention (ASH 2025) - "Initial treatment: nilotinib 800 mg/day, reduced to 200 mg BID due to hematologic toxicity...Started 7+3 (cytarabine + daunorubicin) + ponatinib on 05/20/2025...NGS:WT1 p.C29_L30insCRHPGPEPRSVC* VAF 1.39%, ASXL1 p.G645Vfs*58 VAF 1.55%, ASXL1 p.E929G VAF 1.46% ,ASXL1 p.T936= VAF 1.41%(Tier 1) Started R-HyperCVAD + dasatinib...In the current era of CML targeted therapy with TKIs or myristoyl inhibitors, the presence of associated genetic alterations (AGAs) becomes relevant, as they may predict aggressive behavior and open a window to evaluate transplantation in these patients for better therapeutic responses. Imatinib is not benefical in this patients."

Chronic Myeloid Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Herpes Zoster • Infectious Disease • Leukemia • Liver Failure • Musculoskeletal Pain • Myeloproliferative Neoplasm • Respiratory Diseases • Varicella Zoster • ABL1 • ASXL1 • CD20 • CEBPA • GATA2 • WT1

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML (ASH 2025) - "Pt1: Male, CML diagnosed at age 21; prior TKIs: imatinib, dasatinib, bosutinib; progressed to CML-BC at age 26; no response to ponatinib in monotherapy after two months so asciminib was added for 1 months of combination therapy. The distinct yet complementary mechanisms of TKIs were well tolerated in pt 1 and 2; its use in patients older than 50 years could require caution moreover if precedently treated with nilotinib. These preliminary results warrant further confirmation in larger prospective trials."

Metastases • Chronic Myeloid Leukemia • Myocardial Infarction • ABL1

Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase (ASH 2025) - "Asciminib was used in conjunction with another ATP-binding TKI in 5 (71%) patients (ponatinib, N=4; dasatinib, N=1); three of whom also received additional treatment (venetoclax and hypomethylating agents, N=2; intensive chemotherapy, N=1). Asciminib-based regimen was well tolerated, with only grade 1-2 non-haematological toxicities in 3 patients (hepatotoxicity, N=1; rash, N=1; myalgia, N=1) and grade 2 or above cytopenia in 3 patients.Conclusions The retrospective nature and small cohort size of our study notwithstanding, our analysis of this real-life cohort of CML-BP patients showed promising activity and reassuring safety profile of asciminib-based regimens. Patients experiencing ponatinib failure could potentially be salvaged by asciminib-based treatment."

Monotherapy • Chronic Myeloid Leukemia • Hematological Malignancies • Musculoskeletal Pain • ABL1

Overcoming asciminib resistance by targeting compound BCR::ABL1 mutations in chronic myeloid leukemia (ASH 2025) - "Selected candidate compounds demonstrating efficacy were validated across a panel of CML models, including Ba/F3 cells expressing wild-type BCR::ABL1, the T315I mutant (Ba/F3 T315I), and compound mutations (Ba/F3 PR: Y253H, E255K, and T315I), as well as K562 cells and their drug-resistant derivatives, K562 imatinib-resistant (K562 IR) and K562 ponatinib-resistant (K562 PR). CML cells with compound BCR::ABL1 mutations exhibited resistance to asciminib and, in part, to ponatinib, while bortezomib and selinexor retained efficacy in these resistant cells. Olverembatinib effectively suppressed proliferation and induced apoptosis in ABL TKI-resistant CML cells. The combination of olverembatinib and selinexor synergistically induced apoptosis and suppressed proliferation, offering a promising approach for overcoming TKI-resistant CML with compound mutations."

IO biomarker • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • CASP3 • CASP7

Outcomes with ponatinib in patients with relapsed/refractory Philadelphia-chromosome positive acute lymphoblastic leukemia: A systematic review and meta-analysis (ASH 2025) - "Ponatinib appears to be an effective treatment option in relapsed/refractory Ph+ ALL, demonstrating favorable remission and 1-year survival outcomes with manageable toxicity. Further prospective trials with larger sample sizes and longer follow-up are needed to establish its optimal use and long-term efficacy."

Retrospective data • Review • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Thrombocytopenia

Front‑line ponatinib vs imatinib in newly diagnosed Philadelphia‑positive ALL: Systematic review and meta‑analysis of survival and deep molecular response (ASH 2025) - "This meta-analysis demonstrates that up-front ponatinib substantially increases the likelihood of achieving deep molecular remission and trends toward reducing mortality compared with imatinib in adults with newly diagnosed Ph + ALL. While the survival benefit remains statistically imprecise pending ongoing randomized trials, the magnitude of the CMR advantage and clinically meaningful quality-of-life improvements support considering ponatinib as the preferred first-line TKI in patients with acceptable vascular risk profiles. Further prospective data are required to confirm long-term survival gains and fully characterize the safety profile."

Retrospective data • Review • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Outcomes of concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell ALL (ASH 2025) - "All newly diagnosed pts (n=6) received ABL1 kinase TKI-based induction (ponatinib, n=4; dasatinib, n=1; imatinib, n=1) with hyper-CVAD (n=3), pediatric-inspired regimens (n=2), and blinatumomab-ponatinib (n=1)...However, 2-years later, patient developed flow MRD+ disease and received inotuzumab + ponatinib followed by allo-SCT and died 2-months later from post-transplant complications...Both patients also had ruxolitinib added to the salvage treatment. Concomitant Ph+/CRLF2+ B-ALL represents a rare but high-risk subset with inferior outcomes despite TKI- and immunotherapy-based regimens. Notably, relapses often involved loss of the Ph+ clone with persistence of CRLF2+ disease."

IO biomarker • Acute Lymphocytic Leukemia • Cerebral Hemorrhage • CNS Disorders • Hematological Malignancies • Leukemia • ABL1 • CRLF2 • IKZF1 • JAK2 • NRAS • PTPN11

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations (ASH 2025) - "Anytime during the follow-up period, 67%received dasatinib, 35% ponatinib, 24% imatinib, 13% nilotinib, 6% bosutinib, and 66 (2%) asciminib-based therapy.Based on the index TKI, treatment patterns evolved over time, with important shifts between 2016 and2024...Asciminib was given ascombination therapy (82%) with corticosteroids (76%), chemotherapy (64%), inotuzumab ozogamicin(16%), and blinatumomab (15%). This real-world study described evolving patterns in the management of pts with Ph+ ALL... This real-world study described evolving patterns in the management of pts with Ph+ ALL. Inrecent years, increased use of ponatinib and immunotherapy has been observed alongside a decline inuse of dasatinib and imatinib. Despite therapeutic advances, many pts experienced clinical eventsassociated with TKI-related conditions, and one-third had disease relapse."

Clinical • HEOR • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Ischemic stroke • Leukemia • Myocardial Infarction • Respiratory Diseases

Dynamic mutational evolution and transcriptomic remodeling on 3rd-generation TKI therapy in TKI-resistant patients with chronic myeloid leukemia (ASH 2025) - "Background Third-generation tyrosine kinase inhibitors (3G-TKIs), olverembatinib and ponatinib,improved outcomes for patients with resistant chronic myeloid leukemia (CML). Conclusions Our integrative longitudinal analyses revealed that 3G-TKI therapy induced divergentmolecular trajectories in CML: durable responses were defined by mutation clonal clearance,LSCs suppression and immune activation, whereas resistance was driven by persistent or expandingmutation clones (e.g., ASXL1G646Wfs*12, RUNX1 and PHF6), sustained stemness, and immune-cold states. Transcriptomic remodeling provided a powerful early indicator of therapeutic failure and supportsdynamic molecular monitoring to guide personalized therapy."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • ASXL1 • IFNA1 • PHF6 • RUNX1 • TNFA

Unveiling FLT3 in B-ALL: Molecular drivers and targeted treatment opportunities (ASH 2025) - "In vitro assays withincreasing concentrations of 6 FLT3i for 24, 48, 72h [Gilteritinib (Gil), Midostaurin, Crenolanib, Sorafenib,Quizartinib, Ponatinib (Pon)] and Venetoclax (Ven) were performed on primary patient samples (n=29; FLT3-mut n=5/29), 11 B-ALL wt cell lines, 2 B-ALL mut (NALM6-mut, KASUMI-10), and 4 AML cell lines (OCI-AML3 wt; MV-4-11, MOLM-13, MONO-MAC6 FLT3-mut). FLT3 alterations define a novel Ph-negative B-ALL subgroup withtherapeutic relevance. Given the responses in FLT3-wt in addition to the mutated models, FLT3i may alsobenefit patients without FLT3 muts. Thanks to: Ricerca Corrente by the Italian MoH L3P1946 andAILTreviso."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • T Acute Lymphoblastic Leukemia • FLT3 • IKZF1 • KMT2A • PBX1 • TCF3 • TP53 • ZNF384

Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial (ASH 2025) - "A 71-year-oldpatient with a previous medical history of hypertension developed G5 acute coronary syndrome after 2.5months of asciminib therapy.Overall, 5 of 50 patients (10%) discontinued asciminib after a median of 7.6 months (range, 0.5-16.6) dueto 1) a G3 subacute brain stroke, switched to bosutinib; 2) a G2 and G3 pancreatitis in one patient each,both switched to dasatinib; 3) a G5 acute coronary syndrome (NSTEMI) with cardiogenic shock in a 71-year-old male w; 4) a loss of CCyR after 11.4 months of therapy with the emergence of A337T and F497Lmutations with subsequent switch to ponatinib. The 6-month rates of FFS, EFS, and OS were 93%, 97%,and 97%, respectively.ConclusionThis interim analysis showed very good response rates with asciminib in ND CML after a short follow-upwith MMR and deep molecular response rates of 64% and 42% by 6 months, respectively. Adverseevents, including gastrointestinal, as well as one fatal cardiovascular event, were observed."

P2 data • Acute Coronary Syndrome • Chronic Myeloid Leukemia • Coronary Artery Disease • Hematological Malignancies • Hypertension • Leukemia • Musculoskeletal Pain • Pancreatitis • ABL1

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor (ASH 2025) - "The 10-year EFS, TFS, and OS rates with 1L were 57%, 100%,and 79%, respectively.2L consisted of imatinib in 74 pts (27%), bosutinib in 64 (23%), nilotinib in 57 (21%), dasatinib in 43 (15%),ponatinib in 31 (11%), asciminib in 6 (2%), and investigational drug in 1 (1%). Of 65 pts withtranscripts <0.1%, 59 (91%) maintained their response.The estimated 10-year EFS, TFS, and OS rates on 2L therapy were 67%, 87%, and 71%, respectively.ConclusionOverall, 2L after 1L 2G-TKI resulted in cytogenetic remissions in approximately 80% of the pts andmolecular remissions in more than 60% of the pts. Response rates were significantly higher in pts treatedwith a 3G-TKI compared to a 2G-TKI in the second line."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis (ASH 2025) - "First-line TKI was imatinib in196 pts (48%), nilotinib in 100 (24%), dasatinib in 93 (23%), ponatinib in 16 (4%), and bosutinib in 4 (1%).309 pts electively discontinued TKI (76%), 72 (18%) discontinued therapy due to adverse events, 7 (2%) forpregnancy, 7 (2%) for financial reasons, 6 (1%) due to the diagnosis of another malignancy, and 6 (1%) forother reasons. ConclusionTreatment DC is a safe approach in pts with CML who achieve a prolonged DMR, with no increase in therisk of disease progression or CML-related deaths. A sustained duration of DMR of more than 5 years wasassociated with the highest rates of MRFS and TFR."

Biomarker • Retrospective data • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors (ASH 2025) - "Eligible studies were those reporting the incidence of SMs in adults withchronic-phase CML treated with TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, andasciminib...Data on bosutinib (n=2) and ponatinib (n=1) were limited, while asciminib was notreported in any study... This reviewidentified a notable incidence of SMs, particularly involving prostate, colorectal, lung, and lymphoidcancers. While some variability in cancer types was observed across studies, no consistent associationcould be established between TKI generation or treatment duration and SMs risk.SM development wasassociated with poor prognosis and increased mortality, highlighting the need for proactive surveillance.Large-scale prospective studies are needed to clarify causality, define long-term safety, and informsurvivorship strategies."

Review • Breast Cancer • Chronic Myeloid Leukemia • Colorectal Cancer • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study. (ASH 2025) - "The TKIs that were discontinued first were dasatinib (39.0%), nilotinib(36.6%), imatinib (14.6%) and bosutinib (9.8%). This study suggests that a second TKI discontinuation following ponatinib maintenancetherapy may confer the benefit of successful TFR in certain patients. Notably, patients who initiallydiscontinued imatinib showed a higher TFR rate. Additionally, long-term treatment history and longer TFRduration during the initial TKI discontinuation correlated with a higher TFR rate."

Clinical • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP (ASH 2025) - "Peripheral blood stem cells were used in 84%of cases, with 79% receiving myeloablative conditioning, and 51% receiving total body irradiation.TKI use prior to transplant included imatinib (N=612, 64%), dasatinib (N=210, 22%), nilotinib (N= 96, 10%),and ponatinib (N=40, 4%). In this large, multicenter cohort of patients with Ph+ ALL undergoing allo-HCT in CR1, the useof second- and third-generation TKIs during induction was associated with superior survival outcomescompared to imatinib. Post-transplant TKI prophylaxis significantly improved LFS and OS, regardless ofpre-transplant MRD status. These findings support the incorporation of newer TKIs and prophylacticstrategies in the transplant setting to optimize long-term outcomes in Ph+ ALL."

Clinical • Post-transplantation • Pre-transplantation • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl (ASH 2025) - P1/2 | "A previousphase 1b/2 study of venetoclax, navitoclax and chemotherapy in R/R T-ALL showed 50% CR rate.Therefore, we anticipate a CR rate of 30% in our study, which combines LP-118 with similarchemotherapy backbone. We will include 6 patients from phase 1 portion in our efficacy analysis.Several correlative studies are planned to identify biomarkers of response and resistance, including BH3profiling, molecular genetic profiling (DNA- and RNA-seq), and pre-TCR signaling activity in baseline vsrelapse samples. This investigator-initiated trial is funded by the Leukemia Lymphoma Society AcademicClinical Trials grant."

IO biomarker • P1/2 data • Acute Lymphocytic Leukemia • Anorexia • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Rare Diseases • T Acute Lymphoblastic Leukemia • BCL2 • BCL2L1 • TRB

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial (ASH 2025) - P2 | "In a single-arm Phase II trial weconducted, DA-EPOCH ± rituximab (R) ± TKI yielded comparable morphologic (morph) and measurableresidual disease (MRD)- remissions with less toxicity than seen in a comparable cohort of patientsreceiving hyperCVAD. This study completed accrual in 2021, before routine upfront incorporation ofimmunotherapy and ponatinib (if Ph+)...Imatinib or dasatinib was added if Ph+, and R if CD20+...8 pts (15%) switched to blinatumomab whenMRD+ after DA-EPOCH, with none receiving it when MRD-. DA-EPOCH±R±TKI yields durable remissions, with survival comparable toimmunotherapy-based strategies for ALL... DA-EPOCH±R±TKI yields durable remissions, with survival comparable toimmunotherapy-based strategies for ALL. Unlike many other approaches, outcomes for older pts weresimilar to the general study population. These results support DA-EPOCH±R±TKI as a curative-intentoption, particularly in resource-limited settings."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • ABL1 • CD20

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia (ASH 2025) - "The latest TKI therapy included dasatinib, imatinib, bosutinib, nilotinib, asciminib andponatinib in 34%, 29%, 18%, 11%, 6% and 2% of the patients, respectively. Most importantly, we note that more than 50% of the patientsare on a lower dose TKI in the later line settings without compromising outcomes, highlighting that thereis room for optimization of TKI dosing strategy in CP-CML for improved patient tolerance whilemaintaining outcomes. Larger registry studies are needed to better understand prescription practices ofTKIs in CP-CML."

Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia

Secondary malignancies after hematopoietic cell transplantation for sickle cell disease: A single-center experience (ASH 2025) - "This study aims to describe our single-center experience and evaluate theoccurrence and clinical characteristics of secondary malignancies following HCT in patients with SCD.We conducted a retrospective review of all patients with sickle cell disease (SCD) who underwent non-myeloablative conditioning withalemtuzumab and 300 cGy total body irradiation (TBI) for allogeneic hematopoietic cell transplantation (HCT) at our center...Diagnoses included MDS (n=2), MDS transformed to AML (n=1), CML (n=1), Philadelphia-positive ALL (n=1), and EBV-related PTLDwith stage IV DLBCL (n=1).Summary of Patients with Secondary MalignancyPatientAgeGenderTime post-transplantDiagnosisChimerism atDiagnosisGeneticAbnormalitiesTreatmentCurrentStatusLatestChimerismHbS (%)138Male4.8 yearsGraft failure MDS0%del(7q31),del(13q14),ASXL1, PTPN11,RUNX12nd transplant(FluBu4),AzacitidineMDSrecurrencepost 2nd HCT11%4.1229Female3.5 yearsGraft failurepost 2ndand 3rd..."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Sickle Cell Disease • Transplantation • ASXL1 • PTPN11 • TP53

High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission. (ASH 2025) - P1/2 | "In conclusion, using an external quality control based on 72 samples, we are able to identify a very goodFLT3-ITD MRD technique and to validate the methodology to assess FLT3-ITD MRD with a level ofsensitivity of 10-5/10-4. In this post hoc study, FLT3-ITD was a major predictor of OS and RFS, particularlyif negative at TP1. Patients with delayed later negativity had lower OS and RFS."

Clinical • Combination therapy • Next-generation sequencing • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • NPM1